Thus, the precise molecular and genetic mechanisms of acquired BRAF inhibitor resistance in BRAF V600E melanomas have yet to be defined, and this lack of mechanistic understanding hinders the development of novel chemotherapeutics and combination therapies effective for the treatment of tumors that have become resistant to BRAF inhibitor treatment regimens. The gene discussed is BRAF; the disease is melanoma.